Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.

@article{Frelin2005TargetingNA,
  title={Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells.},
  author={Catherine Frelin and V{\'e}ronique Imbert and Emmanuel Griessinger and A Peyron and Nathalie Rochet and Patrick Philip and Christian Dageville and A. Sirvent and Micha{\"e}l Hummelsberger and Etienne B{\'e}rard and Michel Dreano and Nicolas Sirvent and J N Peyron},
  journal={Blood},
  year={2005},
  volume={105 2},
  pages={804-11}
}
Acute myeloid leukemia (AML) cells are characterized by a constitutive and abnormal activation of the nuclear factor-kappaB (NF-kappaB) transcription factor. This study, conducted in vitro on 18 patients, shows that targeting the IKB kinase 2 (IKK2) kinase with the specific pharmacologic inhibitor AS602868 to block NF-kappaB activation led to apoptosis of human primary AML cells. Moreover, AS602868 potentiated the apoptotic response induced by the current chemotherapeutic drugs doxorubicin… CONTINUE READING